Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QN-01
- Development stage
- Unknown
- Lead developer
- Qnovia
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
QN-01 is a prescription inhaled nicotine replacement therapy (NRT) developed for smoking cessation. It is designed to deliver nicotine via pulmonary inhalation using the proprietary RespiRx drug/device platform, aiming to mimic the rapid nicotine delivery of combustible cigarettes and thereby better alleviate cravings and withdrawal symptoms compared to existing NRTs such as gums or patches. In Phase 1 clinical studies, QN-01 demonstrated dose-dependent pharmacokinetics with higher maximum plasma concentrations (Cmax) and faster time to peak concentration (Tmax) than current inhaled NRTs, suggesting a superior pharmacokinetic profile. The product was well tolerated in healthy adult smokers with no serious adverse events reported. Qnovia plans further development in both the US and UK regulatory pathways[1][3][4][6].
- Brand names
- RespiRx Nicotine InhalerRespiRx
- Other names
- QN-01QN01QN 01RespiRx
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on QN-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QN-01.